Safety signals of zolbetuximab in gastric or gastroesophageal junction adenocarcinoma: a comprehensive analysis of the FDA adverse event reporting system (FAERS) data
BackgroundZolbetuximab is a novel monoclonal antibody targeting CLDN18.2 for advanced gastric or gastroesophageal junction adenocarcinoma. However, its large-scale, real-world safety profile remains incompletely characterized. This study aimed to analyze its post-marketing adverse events using the F...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2026-07-01
|
| Serier: | Frontiers in Oncology |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fonc.2026.1787423/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
